Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 16 | 2023 | 1076 | 1.670 |
Why?
|
| Mouth Neoplasms | 10 | 2023 | 194 | 1.470 |
Why?
|
| Head and Neck Neoplasms | 11 | 2023 | 1052 | 1.010 |
Why?
|
| Neovascularization, Pathologic | 6 | 2010 | 353 | 0.810 |
Why?
|
| Receptor, EphB4 | 2 | 2013 | 24 | 0.550 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 1464 | 0.470 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2009 | 311 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-met | 5 | 2017 | 199 | 0.450 |
Why?
|
| Esophageal Neoplasms | 2 | 2012 | 321 | 0.440 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 265 | 0.330 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 17 | 0.320 |
Why?
|
| Oligopeptides | 1 | 2009 | 179 | 0.320 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 2232 | 0.310 |
Why?
|
| Lung Neoplasms | 6 | 2014 | 2262 | 0.290 |
Why?
|
| Cell Nucleolus | 1 | 2006 | 23 | 0.280 |
Why?
|
| Precancerous Conditions | 2 | 2009 | 196 | 0.280 |
Why?
|
| Cell Line, Tumor | 9 | 2014 | 2426 | 0.280 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2011 | 84 | 0.270 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 157 | 0.260 |
Why?
|
| Cell Movement | 7 | 2016 | 758 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 2 | 2017 | 36 | 0.240 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1753 | 0.230 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2003 | 2 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2009 | 407 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 275 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2016 | 458 | 0.210 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2013 | 153 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1197 | 0.190 |
Why?
|
| Saliva | 1 | 2020 | 122 | 0.180 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1999 | 50 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 2 | 2001 | 301 | 0.160 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.160 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.160 |
Why?
|
| Mice | 8 | 2016 | 11352 | 0.160 |
Why?
|
| Gene Dosage | 3 | 2013 | 207 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 2360 | 0.150 |
Why?
|
| Life Style | 1 | 2018 | 189 | 0.150 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 124 | 0.140 |
Why?
|
| Gene Expression | 3 | 2013 | 1284 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2017 | 268 | 0.140 |
Why?
|
| Gene Expression Profiling | 4 | 2010 | 1384 | 0.140 |
Why?
|
| Calgranulin A | 1 | 2016 | 11 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 1041 | 0.140 |
Why?
|
| Calgranulin B | 1 | 2016 | 16 | 0.140 |
Why?
|
| Humans | 26 | 2023 | 86643 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 1075 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 1169 | 0.120 |
Why?
|
| Animals | 10 | 2022 | 26582 | 0.120 |
Why?
|
| Receptors, Opioid, mu | 1 | 2014 | 45 | 0.120 |
Why?
|
| Indazoles | 1 | 2013 | 68 | 0.120 |
Why?
|
| Niacinamide | 1 | 2013 | 116 | 0.120 |
Why?
|
| Receptors, Growth Factor | 2 | 2011 | 52 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 182 | 0.110 |
Why?
|
| Paxillin | 1 | 2013 | 59 | 0.110 |
Why?
|
| 4-Nitroquinoline-1-oxide | 2 | 2010 | 15 | 0.110 |
Why?
|
| Mice, Inbred CBA | 2 | 2010 | 52 | 0.110 |
Why?
|
| ErbB Receptors | 3 | 2010 | 485 | 0.110 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 53 | 0.110 |
Why?
|
| Focal Adhesions | 1 | 2013 | 69 | 0.110 |
Why?
|
| Carcinogens | 2 | 2010 | 108 | 0.110 |
Why?
|
| Interleukin-8 | 3 | 2008 | 86 | 0.110 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 93 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 589 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2014 | 311 | 0.100 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.100 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 64 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 436 | 0.090 |
Why?
|
| Quinazolines | 1 | 2010 | 220 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 64 | 0.090 |
Why?
|
| Piperidines | 1 | 2010 | 181 | 0.090 |
Why?
|
| Microvessels | 1 | 2009 | 70 | 0.080 |
Why?
|
| Loss of Heterozygosity | 3 | 2017 | 85 | 0.080 |
Why?
|
| Macrophages | 2 | 2002 | 554 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1578 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 266 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 276 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 57 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2011 | 814 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 359 | 0.070 |
Why?
|
| Computational Biology | 1 | 2010 | 528 | 0.070 |
Why?
|
| Disease Progression | 3 | 2014 | 1531 | 0.070 |
Why?
|
| Thrombospondin 1 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 350 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 125 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2010 | 534 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 3679 | 0.060 |
Why?
|
| Keratinocytes | 2 | 2003 | 143 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2014 | 303 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2016 | 790 | 0.060 |
Why?
|
| Culture Media, Conditioned | 2 | 2001 | 104 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1074 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 1939 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2013 | 78 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2013 | 289 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 290 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 241 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2003 | 476 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 126 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2001 | 91 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 263 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2001 | 133 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 879 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 689 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 547 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 427 | 0.050 |
Why?
|
| Mutation | 3 | 2020 | 3968 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 612 | 0.050 |
Why?
|
| Gingival Neoplasms | 1 | 1999 | 1 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 1999 | 22 | 0.040 |
Why?
|
| Male | 4 | 2023 | 40965 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 418 | 0.040 |
Why?
|
| Bacteria | 1 | 2023 | 447 | 0.040 |
Why?
|
| Female | 6 | 2018 | 44532 | 0.040 |
Why?
|
| Apoptosis | 2 | 2016 | 1683 | 0.040 |
Why?
|
| Oral Health | 1 | 2018 | 10 | 0.040 |
Why?
|
| Cell Division | 1 | 1999 | 696 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 50 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 552 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 229 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2017 | 33 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 90 | 0.040 |
Why?
|
| Fibroblasts | 1 | 1999 | 729 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 2705 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Skin | 1 | 1999 | 554 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 526 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 267 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 16 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 76 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1585 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2818 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 95 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 128 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 1047 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 162 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 262 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1577 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 116 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 502 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 486 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 692 | 0.030 |
Why?
|
| Wound Healing | 1 | 2014 | 344 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2438 | 0.030 |
Why?
|
| Models, Biological | 1 | 1999 | 1749 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 56 | 0.030 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.030 |
Why?
|
| Lymphokines | 2 | 2002 | 76 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 1106 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2014 | 370 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2013 | 3241 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2013 | 460 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 615 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 296 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2767 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 969 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 532 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 70 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 70 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 348 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Quinolones | 1 | 2010 | 60 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 639 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 78 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 86 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2062 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2501 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 223 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 82 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 272 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 318 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 279 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 300 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 18415 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 543 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 420 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 782 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 679 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 645 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5417 | 0.020 |
Why?
|
| Middle Aged | 2 | 2018 | 25028 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 592 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 5976 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2330 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1056 | 0.020 |
Why?
|
| United States | 1 | 2018 | 6672 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 8981 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 756 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 8489 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6509 | 0.010 |
Why?
|
| Human Genome Project | 1 | 2003 | 19 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 43 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2002 | 46 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2001 | 71 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 47 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2001 | 156 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 164 | 0.010 |
Why?
|
| Cornea | 1 | 2001 | 69 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2001 | 87 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 2271 | 0.010 |
Why?
|
| Monocytes | 1 | 2002 | 214 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 25648 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 683 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2468 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 2378 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1376 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 3990 | 0.010 |
Why?
|